Literature DB >> 3302704

The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients.

D Bihari, M Smithies, A Gimson, J Tinker.   

Abstract

We hypothesized that inadequate oxygenation of peripheral tissues may be unrecognized in critically ill patients and may worsen their prognosis. To test this hypothesis, we measured oxygen delivery to tissues, oxygen uptake, and the extraction ratio (uptake/delivery) before and during a 30-minute infusion of a vasodilator, prostacyclin (5 ng per kilogram of body weight per minute), in 27 critically ill patients with acute respiratory failure. Prostacyclin produced an increase in oxygen delivery (median value before vs. during infusion, 375 vs. 492 ml of oxygen per minute per square meter of body-surface area, P less than 0.001) that was similar in the 14 patients who survived and the 13 who died. This increase in oxygen delivery was associated with a significantly greater increase in oxygen uptake in the patients who died as compared with the survivors (median increase, 19 vs. 5 percent, P less than 0.001). In the survivors, the oxygen extraction ratio fell (median change, -17 percent; range, -27 to -6 percent) and the mixed venous oxygen tension increased. In the patients who died, the extraction ratio rose (median change, 11 percent; range -24 to +40 percent) and the mixed venous oxygen tension did not change. These data suggest the presence of a substantial oxygen debt in patients who subsequently die. Inadequate tissue oxygenation, which may be difficult to recognize, appears to be an important mechanism contributing to the development of irreversible multiple organ failure and subsequent death in some patients with acute respiratory failure.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3302704     DOI: 10.1056/NEJM198708133170701

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  64 in total

Review 1.  Recognition, treatment and complications of meningococcal disease.

Authors:  F A Riordan; A P Thomson
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.022

Review 2.  Oxygen delivery in the critically ill.

Authors:  J L Vincent
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

3.  Methods of monitoring shock.

Authors:  Ednan K Bajwa; Atul Malhotra; B Taylor Thompson
Journal:  Semin Respir Crit Care Med       Date:  2004-12       Impact factor: 3.119

Review 4.  The haemodynamics of septic shock.

Authors:  L G Thijs; A J Schneider; A B Groeneveld
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

5.  [Aerosolized and intravenous prostacyclin during one-lung ventilation. Hemodynamic and pulmonary effects].

Authors:  M Bund; D Henzler; R Walz; R Rossaint; S Piepenbrock; R Kuhlen
Journal:  Anaesthesist       Date:  2004-07       Impact factor: 1.041

Review 6.  Prevention and therapy of the adult respiratory distress syndrome.

Authors:  B Temmesfeld-Wollbrück; D Walmrath; F Grimminger; W Seeger
Journal:  Lung       Date:  1995       Impact factor: 2.584

Review 7.  Oxygen transport-the oxygen delivery controversy.

Authors:  Jean-Louis Vincent; Daniel De Backer
Journal:  Intensive Care Med       Date:  2004-07-16       Impact factor: 17.440

8.  The acute respiratory distress syndrome: definitions, severity and clinical outcome. An analysis of 101 clinical investigations.

Authors:  P Krafft; P Fridrich; T Pernerstorfer; R D Fitzgerald; D Koc; B Schneider; A F Hammerle; H Steltzer
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

Review 9.  Matching total body oxygen consumption and delivery: a crucial objective?

Authors:  Pierre Squara
Journal:  Intensive Care Med       Date:  2004-09-21       Impact factor: 17.440

10.  Effects of dobutamine on oxygen transport and consumption in the adult respiratory distress syndrome.

Authors:  S L Krachman; R F Lodato; R Morice; G Gutierrez; D R Dantzker
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.